PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Follicular lymphoma

Drugs in development · updated 30 October 2026

Follicular lymphoma: drugs in development

Rare diseasePrevalence 1-5 / 10 000 according to Orphanet · ORPHA:545

As of 30 October 2026 there are 187 active clinical trials (recruiting or ongoing, phases I–III) on 144 drugs for follicular lymphoma. 72 are experimental, that is not yet approved in the United States.

187Active trials
72Experimental drugs
8Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
OdronextamabOrdspono®III5NCT06149286
GolcadomideCC-99282III4NCT06911502
SurovatamigAZD0486III4NCT06549595
OrelabrutinibICP-022III3NCT07719855
MK-1045II–III2NCT07634471
IMM0306III1NCT07355283
SCTB35III1NCT07562022
TQB2825III1NCT07187960
AbexinostatPCI 24781II2NCT03600441
CD19I–II2NCT06213636
NemtabrutinibI–II2NCT03162536
TacabrutidegI–II2NCT05294731
5-HydroxytryptophanII1NCT04160910
ALETA-001I–II1NCT06045910
AutoleucelII1NCT07077512
AVM0703I–II1NCT04329728
AZD5492I–II1NCT06542250
ChidamideTucidinostat, HBI-8000II1NCT06158386
CHO-H01I–II1NCT05950165
CTX112I–II1NCT05643742
EO2463I–II1NCT04669171
IMT-009I–II1NCT05565417
JCAR017II1NCT04245839
LacutoclaxI–II1NCT07609862
LinperlisibII1NCT06158386
MDX2003I–II1NCT07249905
NEO100II1NCT05023018
PsilocybinPsilocybineII1NCT06225232
RocbrutinibI–II1NCT07609862
SHR2554II1NCT06368167
SintilimabSinitilimab, SindilimabII1NCT07077512
SotoclaxII1NCT07550855
VNX-101I–II1NCT06533579
XNW5004II1NCT07545603
ZeprumetostatII1NCT07555470
Zilovertamab vedotinII1NCT05458297
ZuberitamabII1NCT06757894
[18F]fluoropropyl-trimethoprimI1NCT07343934
ABBV-101I1NCT05753501
ABBV-291I1NCT06667687

Sorted by most advanced phase and number of active trials. Showing 40 of 72 drugs.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
RituximabRuxience, RituxanII–III46NCT07634471
CyclophosphamideCyclophosphamid, CytoxanII–III39NCT07634471
LenalidomideRevlimid, lenalinomideIII37NCT05100862
FludarabineFludara, FLUDARABINIII21NCT05371093
ObinutuzumabGazyva®, Gazyvaro®III19NCT05100862
BendamustineBendamustin, BedamustineII–III18NCT07634471
DoxorubicinAdriamycin, DoxorubincinII–III16NCT07634471
PrednisonePredinisone, CortancylII–III16NCT07634471
VincristineVincristin, Oncovin [vincristine]II–III16NCT07634471
MosunetuzumabLunsumio Velo®, Lunsumio®III15NCT04712097
ZanubrutinibBGB-3111, Brukinsa®III14NCT05100862
EpcoritamabEpkinly®, Tepkinly®III12NCT06191744
IbrutinibPCI 32765, Imbruvica®III6NCT01804686
TazemetostatTazverik®III6NCT04224493
Axicabtagene CiloleucelYESCARTAIII5NCT05371093

Sorted by most advanced phase and number of active trials. Showing 15 of 72 drugs.

All 144 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D008224 “Lymphoma, Follicular”. Prevalence: Orphanet.

ItalianoFrançaisDeutsch